Primary and iPSC models that mimic the function and cellular interactions in the lung
Models available
- Primary Human Lung Fibroblasts
- Primary Small Airway Epithelial Cell Model
- In development – alveolar model
- Primary Human Lung Fibroblasts
- Primary Small Airway Epithelial Cell Model
- In development – alveolar model
Measurable outputs
- Extra cellular matrix (ECM) deposition
- Cell number/Proliferation
- Deposition of Collagen I and III
- Detection of α-SMA
- Cell viability and compound toxicity
- TransEpithelial Electrical Resistance (TEER)
- Extra cellular matrix (ECM) deposition
- Cell number/Proliferation
- Deposition of Collagen I and III
- Detection of α-SMA
- Cell viability and compound toxicity
- TransEpithelial Electrical Resistance (TEER)
Applications
- Evaluation of anti-fibrotic properties of new compounds
- Respiratory disease modelling
- Lung toxicity
- Evaluation of anti-fibrotic properties of new compounds
- Respiratory disease modelling
- Lung toxicity
Species
- Human
- Human
Our Models
Human Lung Fibroblasts
Our Fibroblast-to-Myofibroblast Transition (FMT) assay is robust and validated. The 384-well format allows rapid evaluation of multiple compounds and conditions using imaging outputs.
More Information
Human Small Airway Epithelial Cell Model
A robust, physiologically relevant lung air-liquid interface epithelial model to enable scientific research and drug discovery
More Information
Benefits of our model
High-throughput FMT assay
Models that mimic in vivo function
Three donors available per study
Services
Lung Fibroblast-to-Myofibroblast Transition (FMT) assay service
Rapid evaluation of the anti-fibrotic properties of your compound by detection of key fibrotic biomarkers in multiple donors.
Lung Toxicity Assay
Cultured on 3D permeable supports, our fully differentiated, polarised, ALI small airway epithelial cell (SAEC) model allows the addition of xenobiotics to either the apical or basolateral compartments to analyse the resultant effects on epithelial barrier integrity and cytokine release in response to cell damage.
Working with us
Timely service
Our service timelines are short due to the efficiency of our assay. We can provide multiple data points on a single plate in as little as 2 months. Our FMT assay evaluates both collagen I and III as well as α-smooth muscle actin.
Model validation
Our lung tissue model is well-characterised and rigorously validated to ensure the generation of robust and predictive data. Our clients also value our scientific expertise in the analysis and interpretation of data.
How we support our clients
By providing predictive data, we give our clients confidence in their key decision processes using our lung model and our Lung Fibroblast-to-Myofibroblast Transition (FMT) assay service.
Our expertise
Our team is experienced in assay development for drugs targeting the lung with specific knowledge of fibrosis. By combining this knowledge with primary and iPSC cell technology, they have developed assays that can help our customers screen, optimise and select candidates for combating fibrosis.
